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Palermo, ItalyBACKGROUND & AIMS: There is much interest in wheat
sensitivity among people without celiac disease (CD), but little
is known about any risks associated with the condition. We
evaluated the prevalence of autoimmune diseases (ADs) among
patients with nonceliac wheat sensitivity (NCWS), and investi-
gated whether they carry antinuclear antibodies (ANA).
METHODS: We performed a retrospective study of 131 pa-
tients diagnosed with NCWS (121 female; mean age, 29.1 years)
at 2 hospitals in Italy from January 2001 through June 2011.
Data were also collected from 151 patients with CD or irritable
bowel syndrome (IBS) (controls). Patient medical records were
reviewed to identify those with ADs. We also performed a
prospective study of 42 patients (38 female; mean age, 34
years) diagnosed with NCWS from July 2011 through March
2014 at 3 hospitals in Italy. One hundred age- and sex-matched
subjects with CD or IBS served as controls. Serum samples were
collected from all subjects and ANA levels were measured by
immunoﬂuorescence analysis. Participants completed a ques-
tionnaire and their medical records were reviewed to identify
those with ADs. RESULTS: In the retrospective analysis, similar
portions of subjects with NCWS (29%) and CD (29%) devel-
oped ADs (mainly Hashimoto’s thyroiditis, 29 cases), compared
with a smaller proportion of subjects with IBS (4%) (P < .001).
In the prospective study, 24% of subjects with NCWS, 20% of
subjects with CD, and 2% of subjects with IBS developed ADs
(P < .001). In the retrospective study, serum samples tested
positive for ANA in 46% of subjects with NCWS (median titer,
1:80), 24% of subjects with CD (P < .001), and 2% of subjects
IBS (P < .001); in the prospective study, serum samples were
positive for ANA in 28% of subjects with NCWS, 7.5% of sub-
jects with CD (P ¼ .02), and 6% of subjects with IBS (P ¼ .005
vs patients with NCWS). ANA positivity was associated with the
presence of the HLA DQ2/DQ8 haplotypes (P < .001). CON-
CLUSIONS: Higher proportions of patients with NCWS or CD
develop autoimmune disorders, are ANA positive, and showed
DQ2/DQ8 haplotypes compared with patients with IBS.Abbreviations used in this paper: AD, autoimmune disease; ANA, antinu-
clear antibody; DBPC, double-blind placebo-controlled; EmA, anti-
endomysium; IBS, irritable bowel syndrome; NCWS, nonceliac wheat
sensitivity.Keywords: Food Allergy; Gluten Sensitivity; Celiac Disease;
Immune Response.
eliac disease is an immune-based reaction to dietary© 2015 by the AGA Institute
0016-5085/$36.00
http://dx.doi.org/10.1053/j.gastro.2015.05.040Cgluten (storage proteins found in wheat, barley, and
rye) that primarily affects the small intestine in genetically
predisposed patients and resolves when gluten is eliminated
from the diet.1 Although it is not certain whether CD can beincluded among the autoimmune diseases (ADs), in CD pa-
tients circulating autoantibodies (antitissue trans-
glutaminase) are observed and a speciﬁc tissue cell type
(enterocyte) is destroyed by CD8þ T cells.2 In addition,
other ADs have been reported in association with CD in
20%30% of cases.3,4
In the last few years, a new clinical entity has emerged
that appears to include patients who consider themselves to
be suffering from problems caused by wheat and/or gluten
ingestion, even though they do not have CD or wheat al-
lergy.5 This clinical condition has been named nonceliac
gluten sensitivity,6 although in a recent article, we suggested
the more appropriate term nonceliac wheat sensitivity
(NCWS),7 because it is not known to date what component
of wheat actually causes the symptoms. Other areas of doubt
in NCWS regard its pathogenesis, while some papers have
reported intestinal immunologic activation,8–10 others have
linked NCWS to the dietary short chain carbohydrate
(fermentable oligo-di-monosaccharides and polyols) load,11
ruling out an immunologic involvement in NCWS. In the
current study, we therefore compared the risk of autoim-
munity in CD and NCWS patients, evaluating the frequency
of ADs and the frequency of serum antinuclear antibody
(ANA) positivity in these 2 conditions.
Methods
Study Design and Population
The study was divided into 2 different parts: a retrospective
evaluation and a prospective survey. In the ﬁrst, the clinical
charts of NCWS patients attending the outpatient centers of the
Department of Internal Medicine at the University Hospital of
Palermo and the Department of Internal Medicine of the Hos-
pital of Sciacca were reviewed with a retrospective method.
They had all been diagnosed with NCWS between January 2001
and June 2011 and included in a previously published study.12
These charts included speciﬁc sections for associated ADs and
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excluded. Two control groups were selected. The ﬁrst was
composed of 101 celiac disease patients and the second of 50
irritable bowel syndrome (IBS) patients. Both were randomly
chosen by a computer-generated method from subjects diag-
nosed during the same period (20012011) and age- (þ2
years) and sex-matched (þ5%) with the NCWS patients. The
IBS controls had been receiving the same elimination diet as the
NCWS patients and had not shown any clinical improvement;
they belonged to the cohort of subjects we had studied
previously.12
In the second part of the study, we prospectively surveyed
adult patients with an IBS-like clinical presentation, according
to the Rome II criteria, and a deﬁnitive diagnosis of NCWS. The
patients were recruited between July 2011 and March 2014 at
3 centers: the 2 already mentioned and the Gastroenterology
Unit of the ARNAS Civico Hospital of Palermo, Italy. Most of the
patients had been referred due to intestinal symptoms, the
onset of which, they reported, could be related to wheat
ingestion. During the study period, the newly diagnosed NCWS
patients were randomly assigned to one of several studies that
we are currently performing on NCWS. In this way, 42 patients
were recruited. Twenty-two of the patients included in the
current study also agreed to be included in other as yet un-
published studies. Two control groups were again selected. One
included 40 consecutive patients with a new CD diagnosis, sex-
(þ5%) and age-matched (þ2 years) with the NCWS patients,
and enrolled during the prospective study period. The second
group included 50 subjects with IBS unrelated to NCWS or
other types of food intolerance, who were consecutively
recruited during the study period and sex- and age-matched
with the NCWS patients. IBS diagnosis had been made in
accordance with Rome II criteria and none of these subjects
improved on an elimination diet without wheat, cow’s milk, egg,
tomato, or chocolate.
For both the prospective and the retrospective studies,
exclusion criteria were positive antiendomysium (EmA) in the
culture medium of the duodenal biopsies, even if the villi to
crypts ratio in the duodenal mucosa was normal; self-exclusion
of wheat from the diet and refusal to reintroduce it before
entering the study; and other organic gastrointestinal diseases.
Noncelia Wheat Sensitivity Diagnosis
To diagnose NCWS in both the retrospective and the pro-
spective parts, various criteria were adopted. Firstly, all the
patients met the recently proposed criteria13: negative serum
antitissue transglutaminase and EmA IgA and IgG antibodies;
absence of intestinal villous atrophy; IgE-mediated immune-
allergy tests negative to wheat (skin prick tests and/or serum
speciﬁc IgE detection). Other criteria adopted in our patients
were resolution of the IBS symptoms on a standard elimination
diet without wheat, cow’s milk, egg, tomato, chocolate, or other
food(s) causing self-reported symptoms; symptom reappear-
ance on double-blind placebo-controlled (DBPC) wheat chal-
lenge, performed as described previously.12 As in previous
studies, DBPC cow’s milk protein challenge and other “open”
food challenges were also performed12 (for details see
Supplementary Material). Additional inclusion criteria were age
older than 18 years; follow-up duration longer than 9 months
after the initial diagnosis; and at least 2 outpatient visits during
the follow-up period.Celiac Disease Diagnosis
Celiac disease was diagnosed in the presence of positive
serum antitissue transglutaminase and/or EmA antibodies
and duodenal villous atrophy at histologic examination, fol-
lowed by symptom resolution after commencement of the
gluten-free diet.
Outcomes
Serum Antinuclear Antibodies. The frequency of
serum ANA positivity in NCWS and the control groups was
evaluated. ANA was identiﬁed by HEp-2 cells, using an indirect
immunoﬂuorescence technique; a titer of 1:40 or higher was
considered positive and the sera were titered at progressive
dilutions until they became negative.
In the patients included in the prospective study, the ANA
pattern was also classiﬁed as “homogeneous,” “ﬁne speckled,”
or “coarse speckled” and “nucleolar.”
Frequency of Associated Autoimmune Dis-
eases. The clinical chart used for the retrospective study listed
the ADs and physicians had to ﬁll out the speciﬁc ﬁelds. The
hospital records of all patients diagnosed with an autoimmune
disorder were thoroughly examined to ascertain whether the
recognized diagnostic criteria for each disorder had been fulﬁlled.
Questionnaire for Autoimmunity. In the prospective
study, the presence of autoimmune disorders in both the study
and control groups was evaluated by a structured question-
naire and a review of patients’ clinical records. The presence
of one of the following was looked for in all subjects: connective
tissue diseases (eg, rheumatoid arthritis, systemic lupus
erythematosus, dermatomyositis, scleroderma, mixed connec-
tive tissue disease, ankylosing spondylitis, or Sjögren’s disease),
autoimmune endocrinologic diseases (eg, Hashimoto’s
thyroiditis, Graves’ disease, insulin-dependent diabetes melli-
tus, or Addison’s disease), autoimmune hepatitis (types 1, 2 and
3), primary biliary cirrhosis, epilepsy with cerebral calciﬁca-
tion, unexplained cerebellar ataxia, alopecia, psoriasis, atrophic
autoimmune gastritis, immune anemia, neutropenia, or
thrombocytopenia. Age at diagnosis of the diseases and treat-
ments received were recorded in all cases.
Laboratory Methods
Serology for CD, duodenal histology studies, and HLA-DQ
typing were performed in all patients as described previ-
ously12 (see Supplementary Material). Duodenal histology le-
sions were classiﬁed according to Corazza and Villanacci as:
normal mucosa (villi to crypts ratio >3 and CD3þ intra-
epithelial intestinal lymphocytes <25/100 enterocytes), grade
A (villi to crypts ratio >3 and CD3þ intraepithelial intestinal
lymphocytes >25/100 enterocytes), grade B1 (villi to crypts
ratio <3, partial villous atrophy), and grade B2 (total villous
atrophy).14
Statistical Analysis
Data were expressed as mean ± SD when the distribution
was Gaussian and differences were calculated using Student t
test. Otherwise, data were expressed as median and range and
analyzed with the Mann–Whitney U test. Fisher’s exact or the
c2 tests were used where appropriate. The Mantel–Haenszel
test was used to compare the severity of the duodenal histology
damage in NCWS and CD patients. Multiple logistic regression





ATanalysis was performed to evaluate the association between the
presence of serum ANA and the other clinical variables evalu-
ated. P < .05 was considered signiﬁcant. All analyses were
performed using the SPSS software package (version 16.0,
released 2007, SPSS Inc, Chicago, IL).
The study protocol conformed to the ethical guidelines of
the Declaration of Helsinki, was approved by the institution’s
human research committee (University Hospital of Palermo),




After the exclusion of the incomplete clinical records in
which some data were lacking and exclusion of the data of
the patients who had tested positive for EmA antibodies in
the culture of the duodenal mucosa, 131 NCWS patients ofTable 1.Clinical Characteristics of 131 NCWS Patients, 101 CD
Study
NCWS (n ¼ 131)
Age, y, mean ± SD 39.1 ± 11
Sex, female/male, n 121/10
Duration of symptoms, y, median (range) 6.5 (140)
Self-reported wheat intolerance, n (%) 78/131 (59)
Family history of CD, n (%) 10/131 (8)
Coexisting atopic diseases, n (%) 39/131 (30)
Body mass index <20 kg/m2, n (%) 32/131 (24)
Anemia,a n (%) 34/131 (27)
Multiple food sensitivity, n (%) 90/131 (69)
Haplotypes DQ2 or DQ8, n (%) 65/131 (50)
Duodenal histology,b n (%)
Normal 26 (20)
Grade A 105 (80)
Grade B1 0
Grade B2 0
NOTE. CD and IBS controls were randomly chosen by a comp
same period and age- and sex-matched (þ5%) with the NCWS
family members.
aAnemia was deﬁned by hemoglobin values <12 g/dL in female
bDuodenal histology lesions were classiﬁed according to Corazz
CD3þ intraepithelial intestinal lymphocytes <25/100 enterocyte
intestinal lymphocytes >25/100 enterocytes), grade B1 (villi to
villous atrophy).the retrospective cohort were included (see Supplementary
Material). Tables 1 and 2 show the clinical characteristics of
the patients included in the retrospective and in the pro-
spective studies, respectively, in comparison with the con-
trol groups. In general, in NCWS patients, there was a higher
percentage of self-reported wheat intolerance and coexist-
ing atopic diseases than CD controls (P < .001).
Frequency of Positive Serum Antinuclear Antibody
Patients with NCWS were more likely to be ANA positive
than both patients with CD and IBS, in both the retrospec-
tive and prospective studies (Figure 1). In the retrospective
study, NCWS patients showed a very high frequency of
serum ANA (46%), signiﬁcantly higher than in CD (24%)
subjects and IBS (2%) controls (P < .001, for both). Median
values of the ANA titer were 1:80 in both NCWS (range,
1:401:640) and CD (range, 1:401:1280).Controls, and 50 IBS Controls Included in the Retrospective
CD (n ¼ 101) IBS (n ¼ 50) P value
40.1 ± 12.3 38.8 ± 10.8 Not applicable,
matching factor
91/10 44/6 Not applicable,
matching factor
5.5 (130) 6 (125) NCWS vs CD, P ¼ .8
NCWS vs IBS, P ¼ .8
CD vs IBS, P ¼ .8
20/101 (20) 8/50 (16) NCWS vs CD, P < .001
NCWS vs IBS, P < .001
CD vs IBS, P ¼ .6
17/101 (17) 0/50 NCWS vs CD, P ¼ .04
NCWS vs IBS, P ¼ .06
CD vs IBS, P ¼ .01
10/101 (10) 3/50 (6) NCWS vs CD, P < .001
NCWS vs IBS, P < .001
CD vs IBS, P ¼ .5
26/101 (26) 4/50 (8) NCWS vs CD, P ¼ .9
NCWS vs IBS, P ¼ .02
CD vs IBS, P ¼ .02
52/101 (52) 3/50 (6) NCWS vs CD, P < .001
NCWS vs IBS, P < .001
CD vs IBS, P < .001
Not evaluated Not evaluated
101/101 (100) 14/50 (28) NCWS vs CD, P < .001
NCWS vs IBS, P < .001
CD vs IBS, P < .001





uter-generated method from subjects diagnosed during the
patients. Family history of CD was evaluated in ﬁrst-degree
s and <13 g/dL in males.
a and Villanacci as: normal mucosa (villi to crypts ratio >3 and
s), grade A (villi to crypts ratio >3 and CD3þ intraepithelial
crypts ratio <3, partial villous atrophy) and grade B2 (total







(n ¼ 50) P value
Age, y, mean ± SD 34 ± 12 35.5 ± 11.3 33.1 ± 7.6 Not applicable,
matching factor
Sex, female/male, n 38/4 35/5 43/7 Not applicable,
matching factor
Duration of symptoms, y, median (range) 5.3 (135) 5.0 (120) 5.4 (128) NCWS vs celiac disease, P ¼ .77
NCWS vs IBS, P ¼ .79
Celiac disease vs IBS, P ¼ .81
Self-reported wheat intolerance, n (%) 30/42 (71) 9/40 (22) 8/50 (16) NCWS vs celiac disease, P < .001
NCWS vs IBS, P < .001
Celiac disease vs IBS, P ¼ .43
Family history of celiac disease, n (%) 8/42 (19) 6/40 (15) 0/50 NCWS vs celiac disease, P ¼ .77
NCWS vs IBS, P ¼ .01
Celiac disease vs IBS, P ¼ .01
Coexisting atopic diseases, n (%) 14/42 (33) 6/40 (15) 4/50 (8) NCWS vs celiac disease, P ¼ .07
NCWS vs IBS, P ¼ .01
Celiac disease vs IBS, P ¼ .32
Body mass index
<20 kg/m2, n (%)
10/42 (24) 10/40 (25) 4/50 (8) NCWS vs celiac disease, P ¼ 1
NCWS vs IBS, P ¼ .05
Celiac disease vs IBS, P ¼ .04
Anemia,a n (%) 14/42 (33) 16/40 (40) 3/50 (6) NCWS vs celiac disease, P ¼ .6
NCWS vs IBS, P < .001
Celiac disease vs IBS, P < .001
Multiple food sensitivity, n (%) 18/42 (43) Not evaluated Not evaluated
Haplotypes DQ2 or DQ8, n (%) 23/42 (55) 40/40 (100) 17/50 (34) NCWS vs celiac disease, P < .001
NCWS vs IBS, P ¼ .05
Celiac disease vs IBS, P < .001
Duodenal histology,b n (%) Not evaluated P < .001
Normal 17 (41) 0
Grade A 25 (59) 0
Grade B1 0 28 (70)
Grade B2 0 12 (30)
NOTE. Celiac disease and IBS controls were randomly chosen by a computer-generated method from subjects diagnosed
during the same period, and age- and sex-matched (þ5%) with the NCWS patients. Family history of celiac disease was
evaluated in ﬁrst-degree family members.
aAnemia was deﬁned by hemoglobin values <12 g/dL in females and <13 g/dL in males.
bDuodenal histology lesions were classiﬁed according to Corazza and Villanacci as: normal mucosa (villi to crypts ratio >3 and
CD3þ intraepithelial intestinal lymphocytes <25/100 enterocytes), grade A (villi to crypts ratio >3 and CD3þ intraepithelial
intestinal lymphocytes >25/100 enterocytes), grade B1 (villi to crypts ratio <3, partial villous atrophy), and grade B2 (total
villous atrophy).
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where the frequency of ANA positivity was higher in
NCWS patients (28%) than in the 2 control groups (7.5%
in CD, P < .02 and 6% in IBS patients, P < .005). The ANA
titer ranged between 1:40 and 1:1280 in both groups. The
ANA pattern in the prospective study was equally
distributed: “homogeneous” in 11 cases, “ﬁne speckled” in
11 cases, “coarse speckled” in 9 cases, and “nucleolar” in
11 cases.Variables Associated With Serum Antinuclear
Antibody Positivity
The presence of serum ANA in NCWS patients correlated
with HLA DQ2/DQ8 haplotypes. In detail, in theretrospective study, HLA DQ2/DQ8 haplotypes were pre-
sent in 49 of 59 ANA-positive vs 16 of 72 ANA-negative
patients (P < .001). A signiﬁcant correlation was also
observed with a high frequency of duodenal lymphocytosis
(P ¼ .02) (Figure 2). No correlation was found with sex, age,
disease duration, presence of coexisting atopic diseases,
multiple food sensitivity, anemia, or body mass index <20
kg/m2. On multivariate analysis, the only variable signiﬁ-
cantly associated with ANA positivity was the presence of
the HLA DQ2/DQ8 haplotypes (odds ratio ¼ 3.5; 95%
conﬁdence interval: 1.65.8; P < .001).
The prospective study conﬁrmed the association
between ANA positivity and HLA status: HLA DQ2/DQ8
haplotypes were present in 10 of 12 ANA-positive vs 13 of
30 ANA-negative patients (P ¼ .04). Again, no other
Figure 1. Frequency of
HLA haplotypes DQ2 and/
or DQ8-positive serum
ANAs and ADs in 131
NCWS patients, 101 CD
controls, and 50 IBS con-
trols, included in the
retrospective study (A) and
in 42 NCWS patients, 40
CD controls, and 50 IBS
controls, included in the
prospective study (B). (A)
Serum ANA positivity:
NCWS vs CD, P < .001;
NCWS vs IBS, P < .001;
CD vs IBS, P < .001. Fre-
quency of ADs: NCWS vs
CD, P ¼ .17; NCWS vs
IBS, P < .001; CD vs IBS,
P ¼ .01. (B) Serum ANA
positivity: NCWS vs CD,
P ¼ .02; NCWS vs IBS,
P ¼ .005; CD vs IBS, P ¼
.68. Frequency of ADs:
NCWS vs CD, P ¼ .8;
NCWS vs IBS, P ¼ .002;
CD vs IBS, P ¼ .01.
Figure 2. Percentage of DQ2/DQ8-positive patients and
grade A duodenal histology (normal villi to crypts ratio with
intraepithelial lymphocytes >25/100 enterocytes) in NCWS
patients showing serum ANA positivity (59 cases) or serum
ANA negativity (72 cases).





ATvariables correlated with ANA positivity, including duodenal
lymphocytosis.Frequency of Associated Autoimmune Diseases
Patients with NCWS showed a frequency of AD similar to
CD, but signiﬁcantly higher than IBS controls, in both the
retrospective and prospective studies (Figure 1). In the
retrospective study, NCWS patients had an associated AD in
29% of the cases vs 21% in CD patients, and both these
groups had a higher frequency than IBS controls (NCWS vs
IBS, P < .001; CD vs IBS, P < .01). In detail, NCWS patients
presented one or more of the following diseases: Hashi-
moto’s thyroiditis (29 cases), psoriasis (4 cases), type 1
diabetes (4 cases), mixed connective tissue disease (1 case),
and ankylosing spondylitis (1 case).
In the prospective study, the frequency of AD was also
virtually identical to that of the retrospective study. Ten
NCWS patients showed concomitant autoimmune thyroiditis
(24%), but no other ADs were found.
In all NCWS patients, the diagnosis of thyroiditis had
been made before that of NCWS (median time, 8 years).
Eight of the ten patients with NCWS and thyroiditis pre-
sented hypothyroidism and were receiving replacement
therapy.
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Autoimmune Diseases
Different trends in the presence of ADs were observed in
the 2 study parts.
In the retrospective study, the presence of ADs in NCWS
patients did not correlate with any of the other variables
studied, including the presence of haplotypes DQ2/DQ8,
which were present in 19 of 38 patients (50%) with ADs
and in 40 of 93 (43%) NCWS patients without an associated
AD. However, in the prospective study, there was a trend
toward an association with thyroiditis in NCWS patients and
the presence of the haplotypes DQ2/DQ8 in 8 of 10 patients
(80%) with thyroiditis and in 15 of 32 patients (47%)
without thyroiditis, but this association was not statistically
signiﬁcant (P ¼ .08).
Regarding the possible association between serum
ANA positivity and presence of ADs, different results were
also found. In the retrospective study, serum ANAs were
present in 20 of 38 (53%) patients with ADs and in 39 of
93 without ADs (42%) (P ¼ .33). In contrast, in the pro-
spective study, ANA positivity was associated with
thyroiditis: 6 of 10 with thyroiditis vs 6 of 32 without
thyroiditis (P ¼ .02).
No other variables signiﬁcantly correlated with the
presence of ADs in either of the 2 study parts, including
duodenal lymphocytosis, which was present only in 15 of
the 38 NCWS patients with AD in the retrospective study
and in 4 of the 10 with AD in the prospective study.
Discussion
NCWS is an emerging clinical condition that, in the last
few years, has attracted the interest of researchers.6,13
There are considerable data, including from the current
study, that seem to indicate that it is a sex-related disease,
with a much higher frequency in females.9,12,14 However,
the lack of a diagnostic marker for NCWS is the main
problem in identifying patients. In addition, after basing the
diagnosis on DBPC challenge, many clinical characteristics
still remain to be deﬁned, including whether NCWS is
associated with nutritional problems or ADs, as is the case
for CD. Recent data have demonstrated that nutrient deﬁ-
ciency is present in about 18% of NCWS patients,15 and we
showed that a low body mass index and reduced bone mass
density are frequent in these patients.16 Data about auto-
immunity in NCWS are very scarce, no past studies have
been speciﬁcally designed to clarify this aspect and, in
particular, no previous investigations have studied the
presence of serum autoantibodies.
We therefore retrospectively evaluated the frequency
of serum ANA positivity in NCWS patients diagnosed by
DBPC challenge in a historical cohort studied in the years
20012011. Serum ANA was positive in 46% of the NCWS
patients, a percentage signiﬁcantly higher than those
observed in the celiac (24%) and IBS controls (2%). In
addition, the ﬁndings obtained in the prospective cohort,
although collected in a small group of NCWS patients, also
conﬁrmed that NCWS is characterized by a higher fre-
quency of positive serum ANA than in CD (28% vs 7.5%).Literature data have reported a frequency of positive au-
toantibodies in CD patients of about 25%, although the
speciﬁc frequency of ANA positivity was about 8%.17,18
The data in healthy controls, using the IF (immunoﬂuo-
rescence) method, have shown ANA positivity in a rela-
tively high proportion of individuals: >10% at 1:80
dilution.19,20 However, although the reported frequency of
positive serum ANA in the general population was high, the
frequency we observed in the NCWS was evidently even
higher. We also found ANA-positive sera at a low dilution
(median, 1:80) and in the absence of speciﬁc signs or
symptoms of overt ADs, in particular systemic lupus
erythematosus.
ANA positivity in our patients was found to be associ-
ated with the presence of the DQ2/DQ8 haplotypes and, to a
lesser extent, with the presence of duodenal lymphocytosis
(grade A histology). Obviously, these associations strongly
suggest a celiac condition, but it must be emphasized that all
the patients we included were negative for CD-speciﬁc an-
tibodies and showed normal intestinal villi when evaluated
after a prolonged time on a gluten-containing diet (at least
100 g wheat per day, for a minimum of 4 weeks). In addi-
tion, we also excluded patients, both from the retrospective
and from the prospective cohorts, who tested positive for
EmA antibodies in the culture medium of the duodenal bi-
opsies, a positive result that could precede the onset of
overt CD.21 However, it has been reported that analysis of
the intraepithelial intestinal lymphocyte ﬂow cytometric
pattern is an accurate method for identifying CD in the
initial diagnostic biopsy of seronegative patients presenting
with lymphocytic enteritis, and it seems to be better than
antitissue transglutaminase 2 intestinal deposits.22
Therefore, a more accurate evaluation of the duodenal his-
tology, using this method, should be recommended in all
NCWS patients that show the DQ2 or the DQ8 haplotypes
and duodenal lymphocytosis.
We also found a quite high frequency of autoimmune
thyroiditis associated with NCWS in both cohorts (22% and
24% in the retrospective and in the prospective cohorts,
respectively), although other ADs—more frequently psori-
asis and type 1 diabetes mellitus—were reported more
rarely in the retrospective cohort. Previous studies have
reported conﬂicting data about the presence of autoimmune
comorbidities in NCWS patients. These were not reported in
2 studies involving a relatively low number of patients,23,24
but a recent multicenter Italian study including nearly 500
patients reported a high prevalence of Hashimoto’s
thyroiditis,25 and the same study showed that other auto-
immune conditions, such as psoriasis, can coexist in these
patients, as reported previously in a clinical setting recalling
NCWS.26 In this respect, our study design with a structured
questionnaire and based on a review of patients’ clinical
records, both dedicated to ascertain the presence of auto-
immune comorbidities, showed that NCWS might behave in
a similar way to CD.3,4
Once again, these ﬁndings pose the question of whether
there is a real distinction between NCWS and CD, and sug-
gest a possible overlap between these 2 conditions. How-
ever, it should be emphasized that the majority of the ADs





ATwere found in patients with absolutely normal duodenal
histology and this is hard evidence that NCWS is an
immune-mediated condition different from CD.
Another strong immunologic hypothesis to consider is
the one suggested by Junker et al, who identiﬁed the
amylase/trypsin inhibitors as activators of innate immune
responses by engaging the Toll-like receptor system.27 In
fact, it has been demonstrated that patients with heredi-
tary angioedema tend to produce autoantibodies and have
a propensity to develop immunoregulatory disorders,
probably due to the increased activation of B cells,
which was found to be associated with a high ex-
pression of TLR-9.28 Whether similar mechanisms have a
role in NCWS autoimmunity obviously remains to be
demonstrated.
Despite the interesting results, however, the limits of our
study must be emphasized. We studied patients referred to
tertiary centers with experience in CD and NCWS and this
factor clearly led to a selection bias, therefore, our results
cannot be extended to the broad population of self-treated
or diagnosed NCWS patients. In addition, in this respect,
we and others have suggested that NCWS cannot be
considered a unique condition, but rather an “umbrella”
term that includes various conditions with different types of
pathogenesis.12,29–33 Regarding our previous hypothesis
that NCWS could be an allergic disease,28 it should also be
remembered that negative IgE test results cannot exclude
food allergy. In the absence of speciﬁc biomarkers, we
should cautiously indicate that this high frequency of
autoimmunity can apply to NCWS patients who react to a
challenge with a low amount of wheat (equivalent to about
20 g bread in our experiment). Finally, it is noteworthy that,
of the 273 patients included in the original cohort of the
retrospective study, 123 (44%) were excluded because the
data in their charts concerning a possible associated con-
dition secondary to autoimmunity were incomplete. We
cannot rule out the possibility that if the clinical records had
been complete, they would have included patients with
clinical characteristics pointing to associated autoimmune
features.
The strong points of our data, on the other hand, were
the patient selection (based on a NCWS diagnosis made by
using the DBPC challenge method), the study design (which
was speciﬁcally constructed to reveal the presence of ADs
and the frequency of serum ANA positivity), and the
conﬁrmation of the retrospective results by the prospective
ones.
In conclusion, our data showed a strong tendency to-
ward autoimmunity in the NCWS patients, characterized by
both associated ADs and the presence of serum ANA posi-
tivity, which, in turn, was correlated with the HLA DQ2/DQ8
haplotypes.
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Supplementary Material
Elimination Diet and Double-Blind
Placebo-Controlled Challenge
On entering the study, all patients commenced a stan-
dard elimination diet, with the exclusion of wheat, cow’s
milk, eggs, tomato, and chocolate. Patients self-reporting
food hypersensitivity were also asked to avoid ingestion
and/or contact with the food(s) causing symptoms. Food
diaries were maintained by the patients during the elimi-
nation diet period to assess dietary intake and adherence to
the diet. After 4 weeks on the elimination diet, they un-
derwent DBPC challenges. The challenges were performed
with the reintroduction of a single food at a time. Patients
were randomized to receive either the “active food” or the
placebo, according to a computer-generated order, deter-
mined by an observer not involved in the study.
In the case of wheat, the DBPC challenge was performed
with capsules coded A or B containing wheat or xylose,
respectively. Capsules A or B were given for 2 consecutive
weeks and then after 1 week of washout the patients
received the other capsules for another 2 weeks (cross-over
design). Wheat challenge was performed administering a
daily dose of 13 g ﬂour, equal to about 20 g bread. A total
of 12 capsules daily were given 3 times daily, away
from meals.
DBPC for cow’s milk was performed by administering
capsules coded as A or B containing milk proteins (casein
from bovine milk, lactoalbumin, lactoglobulin; daily dose 6
g, equal to about 200 mL cow’s milk) or xylose, respectively.
A total of 6 capsules daily were given 3 times daily, away
from meals.
The codes of the capsules were broken only at the end of
the study and the investigators did not know the content of
the capsules during the study period. Challenges for other
foods in patients with suspected multiple food hypersensi-
tivity were performed in an open fashion.
During all phases of the study, including the challenge
period, the severity of symptoms was recorded: the patients
completed a 100-mm visual analog scale, with 0 represent-
ing no symptoms, which assessed overall symptoms and the
speciﬁc symptoms they each reported.
The challenges were stopped when clinical reactions
occurred (increase in visual analog scale score >30) for at
least 2 consecutive days (onset of abdominal discomfort or
pain, associated with a change in stool frequency and/or
stool appearance). The challenges were considered positive
if the same symptoms that had been present initially reap-
peared after their disappearance on elimination diet.
Laboratory Methods for Celiac Disease Diagnosis
On entering the study, all patients underwent serum
antitissue transglutaminase IgA and IgG, EmA IgA, and
anti-gliadin IgA and IgG assays, performed using commercial
kits (Eu-tTG IgA, anti-endomysium, and anti-gliadin IgA and
IgG; Eurospital Pharma, Trieste, Italy). Patients were also
typed for HLA-DQ phenotypes by polymerase chain reaction
using sequence-speciﬁc primers, with a rapid method (DQ-
CD Typing Plus by BioDiaGene, Palermo, Italy).
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